CAROLINA GUTIERREZ to Antineoplastic Agents
This is a "connection" page, showing publications CAROLINA GUTIERREZ has written about Antineoplastic Agents.
Connection Strength
0.200
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
Score: 0.081
-
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer. 2015 Apr; 15(2):101-9.
Score: 0.057
-
HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011 Jan; 135(1):55-62.
Score: 0.043
-
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.
Score: 0.011
-
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May 02; 99(9):694-705.
Score: 0.008